Şirket yükleniyor
Just reported
Q3 2026 results
From Co.-Diagnostics's results release of 10 Kasım 2026; its quarterly report has since been filed.
Revenue
Actual
$282,9K
+%95 y/y
+%70 q/qGuided
—
No guide given
EPS, GAAP
Actual
-$1,01
Guided
—
No guide given
Operating income, GAAP
Actual
-$6,3M
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
Keep exploring
The themes Co.-Diagnostics is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Highest-graded in Medical Devices
Graded A or B and worth $2B or more: A first, then the largest.
MDTMedtronic plc$129,2BA+
SYKStryker Corp.$118,9BA+
EWEdwards Lifesciences Corporation$60,9BA+
GEHCGE Healthcare Technologies Inc.$37BA
GKOSGlaukos Corp$14,6BA
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21 Eki 2026CBGraded C, now B
MCKMckesson Corporation4 Kas 2026BAGraded B, now A
CVSCVS Health Corp4 Kas 2026BAGraded B, now A- EWEdwards Lifesciences Corporation4 Kas 2026BAGraded B, now A
BIIBBiogen Inc.28 Eki 2026BAGraded B, now A
Co.-Diagnostics, Inc. şirketinin ABD Menkul Kıymetler ve Borsa Komisyonu’na (SEC) sunduğu kendi belgelerinden kuruldu. Rakamlar bildirildiği gibidir; hisse başına geçmiş bugünkü hisse tabanına göre yeniden hesaplanmıştır. Bu bir işletmeyi anlatır — yatırım tavsiyesi değildir ve alma ya da satma önerisi değildir.
